Cancer Family
Solid Neoplasm
CI-CAN-00000052Explore in graph →
Non-malignant1,823 active trials28 evidence items
- NCIt
- C9292
Loading cancer entity…
Cancer Family
CI-CAN-00000052Explore in graph →
Clinical trials
6,089 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06008288 | A Phase II Study Evaluating JAB-21822 Monotherapy in Adult Patients With Pancreatic Cancer and Other Solid Tumors Harboring the KRAS p.G12C Mutation. | recruiting | Phase 2 | 88 | Allist Pharmaceuticals, Inc.INDUSTRY | 1 | Mar 13, 2026 | clinicaltrials |
| NCT06736704 | SNV4818 in Participants With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 320 | Pikavation Therapeutics, Inc.INDUSTRY | 3 | Mar 13, 2026 | clinicaltrials |
| NCT07466160 | A Phase Ib/II Study of 7MW3711 Combined With JS207 in Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 280 | Mabwell (Shanghai) Bioscience Co., Ltd.INDUSTRY | 1 | Mar 12, 2026 | clinicaltrials |
| NCT07018622 | Protecting the Kidney's Proximal Tubules From Platinum-Based Chemotherapy Toxicity(DAPA-ARMOR) | recruiting | Phase 2 | 46 | Instituto Nacional de Ciencias Medicas y Nutricion Salvador ZubiranOTHER | 1 | Mar 11, 2026 | clinicaltrials |
| NCT07035249 | DCSZ11 in Combination With Standard Therapy in Advanced or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 9 | West China HospitalOTHER | 1 | Mar 11, 2026 | clinicaltrials |
| NCT07417189 | A Phase I/II Study of ABSK141 in Patients With Advanced Solid Tumors ( ABSK141-101 ) | recruiting | Phase 1 / Phase 2 | 401 | Abbisko Therapeutics Co, LtdINDUSTRY | 1 | Mar 11, 2026 | clinicaltrials |
| NCT04723810 | TumorGlow Intraoperative Molecular Imaging (IMI) | recruiting | Phase 1 / Phase 2 | 500 | University of PennsylvaniaOTHER | 1 | Mar 9, 2026 | clinicaltrials |
| NCT07069062 | A Phase I/Ⅱ Human Study of HY0001a for Injection in Adult Participants With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 261 | Sichuan Huiyu Pharmaceutical Co., LtdINDUSTRY | 1 | Mar 9, 2026 | clinicaltrials |
| NCT06895031 | Study of JYP0015 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS(STAR) | recruiting | Phase 2 | 210 | Guangzhou JOYO Pharma Co., LtdINDUSTRY | 1 | Mar 6, 2026 | clinicaltrials |
| NCT06667960 | Study of JK06 in Patients With Unresectable Locally Advanced or Metastatic Cancer | recruiting | Phase 1 / Phase 2 | 255 | Salubris Biotherapeutics IncINDUSTRY | 2 | Mar 5, 2026 | clinicaltrials |
| NCT07222631 | SB-4826 in Adult Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphomas | recruiting | Phase 1 / Phase 2 | 48 | University of California, San DiegoOTHER | 1 | Mar 5, 2026 | clinicaltrials |
| NCT07028281 | A Trial of SHR-4849 Combined With Other Antitumor Drugs in Patients With Malignant Solid Tumors | recruiting | Phase 2 | 120 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Mar 3, 2026 | clinicaltrials |
| NCT04469530 | Sirolimus in Combination With Metronomic Chemotherapy in Children With High-Risk Solid Tumors(AflacST1903) | recruiting | Phase 2 | 55 | Emory UniversityOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT06410209 | A Culturally-Tailored Mobile Health and Social Media Physical Activity Intervention for Improving Physical Activity in Hispanic or Latino/Latina Adolescent and Young Adult Childhood Cancer Survivors, Walking Juntos Study | recruiting | Phase 2 | 190 | Children's Oncology GroupNETWORK | 2 | Feb 27, 2026 | clinicaltrials |
| NCT07433283 | Carbon Nanoparticle-Loaded Iron in the Treatment of Advanced Solid Tumor | recruiting | Phase 1 / Phase 2 | 54 | Sichuan Enray Pharmaceutical Sciences CompanyOTHER | 1 | Feb 25, 2026 | clinicaltrials |
| NCT06358677 | Topical Tretinoin Prophylaxis for Anti-EGFR Induced Skin Toxicity in Patients With Solid Tumors(FACE) | recruiting | Phase 2 | 25 | University of UtahOTHER | 1 | Feb 13, 2026 | clinicaltrials |
| NCT07328217 | A Phase 1/2 Study of GW5282 in Participants With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 203 | Dizal PharmaceuticalsINDUSTRY | 1 | Feb 11, 2026 | clinicaltrials |
| NCT04930432 | Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors | recruiting | Phase 1 / Phase 2 | 400 | Betta Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Feb 10, 2026 | clinicaltrials |
| NCT06634849 | An Open Label Dose Finding Study of PTT-4256 in Patients With Solid Tumours (RAISIC-1). | recruiting | Phase 1 / Phase 2 | 30 | Pathios Therapeutics Pty LtdINDUSTRY | 1 | Feb 10, 2026 | clinicaltrials |
| NCT06534190 | CD8 PET Imaging in Metastatic Solid Tumours | recruiting | Phase 2 | 30 | University Medical Center GroningenOTHER | 3 | Feb 9, 2026 | clinicaltrials |
| NCT07392736 | A Phase I/IIa Study of AL8326 Combined With Toripalimab in the Treatment of Advanced Solid Tumors. | recruiting | Phase 1 / Phase 2 | 228 | Advenchen Laboratories, LLCINDUSTRY | 1 | Feb 6, 2026 | clinicaltrials |
| NCT03465592 | Trial of Nivolumab Following Partially Human Leukocyte Antigen (HLA) Mismatched BMT in Children & Adults With Sarcoma | recruiting | Phase 1 / Phase 2 | 39 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT07359066 | An Open-label, First-in-Human, Dose-Escalation and Dose-Expansion Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SPR1020 in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 210 | Shanghai SciBrunch Therapeutics Co., Ltd.INDUSTRY | 1 | Feb 5, 2026 | clinicaltrials |
| NCT07382531 | OH2 Injection in Combination With BS006 Injection for Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 30 | Binhui Biopharmaceutical Co., Ltd.INDUSTRY | 1 | Feb 4, 2026 | clinicaltrials |
| NCT06697197 | A Study of BMS-986482 Alone or as Combination Therapy in Participants With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 413 | Bristol-Myers SquibbINDUSTRY | 9 | Feb 3, 2026 | clinicaltrials |
| NCT04390737 | Evaluate the Safety and Clinical Activity of HH2853 | recruiting | Phase 1 / Phase 2 | 254 | Haihe Biopharma Co., Ltd.INDUSTRY | 2 | Jan 30, 2026 | clinicaltrials |
| NCT07148128 | Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of WEF-001 as Monotherapy in Advanced KRAS-Mutant Solid Tumours. | recruiting | Phase 1 / Phase 2 | 110 | Auricula Biosciences Inc.INDUSTRY | 3 | Jan 29, 2026 | clinicaltrials |
| NCT06208657 | Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent Cancer | recruiting | Phase 1 / Phase 2 | 90 | Australian & New Zealand Children's Haematology/Oncology GroupOTHER | 2 | Jan 28, 2026 | clinicaltrials |
| NCT07151040 | Phase 1/2 Study to Evaluate TH9619 in the Treatment of Advanced Solid Tumors(ODIN) | recruiting | Phase 1 / Phase 2 | 43 | One-carbon Therapeutics ABINDUSTRY | 3 | Jan 28, 2026 | clinicaltrials |
| NCT07371663 | An Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 266 | Beijing Tide Pharmaceutical Co., LtdINDUSTRY | 1 | Jan 28, 2026 | clinicaltrials |
| NCT05867420 | A Study of ASKG915 in Patients With Selected Advanced Solid Tumors. | recruiting | Phase 1 / Phase 2 | 594 | AskGene Pharma, Inc.INDUSTRY | 2 | Jan 27, 2026 | clinicaltrials |
| NCT07093970 | A Study of MRG006A in the Treatment of Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 343 | Lepu Biopharma Co., Ltd.INDUSTRY | 1 | Jan 22, 2026 | clinicaltrials |
| NCT06959615 | A Phase I/IIa Study of JAB-23E73 in Patients With Advanced Solid Tumors Harboring KRAS Gene Alteration | recruiting | Phase 1 / Phase 2 | 334 | Jacobio Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Jan 20, 2026 | clinicaltrials |
| NCT06973564 | JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration | recruiting | Phase 1 / Phase 2 | 294 | Jacobio Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Jan 16, 2026 | clinicaltrials |
| NCT07253116 | A Phase I/II Clinical Study of WJ22096 Tablets in Patients With Advanced Tumors | recruiting | Phase 1 / Phase 2 | 20 | Nanjing Jingao biomidical technology Co. Ltd.INDUSTRY | 1 | Jan 14, 2026 | clinicaltrials |
| NCT03829254 | A Safety, Pharmacokinetic and Clinical Activity Study of NUC-7738 in Patients With Advanced Solid Tumours and Lymphoma | recruiting | Phase 1 / Phase 2 | 135 | NuCana plcOTHER | 1 | Jan 12, 2026 | clinicaltrials |
| NCT07268040 | A Trial of SHR-7787 Injection Combined With Other Anti-tumor Drugs in Patients With Malignant Solid Tumors | recruiting | Phase 2 | 400 | Shanghai Hengrui Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jan 12, 2026 | clinicaltrials |
| NCT05490472 | JAB-2485 Activity in Adult Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 102 | Jacobio Pharmaceuticals Co., Ltd.INDUSTRY | 2 | Jan 9, 2026 | clinicaltrials |
| NCT06737731 | A Phase I/II Clinical Study of SHR-1681 for Injection in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 300 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Jan 9, 2026 | clinicaltrials |
| NCT07258160 | Evaluation of the Effect of Cordycepin on CD8+ Lymphocytopenia in Patients With Solid Tumors | recruiting | Phase 2 | 127 | Second Affiliated Hospital of Soochow UniversityOTHER | 1 | Jan 9, 2026 | clinicaltrials |
| NCT06265727 | A Phase 1/2 Study to Investigate CRB-701 in Solid Tumors | recruiting | Phase 1 / Phase 2 | 348 | Corbus Pharmaceuticals Inc.INDUSTRY | 7 | Jan 8, 2026 | clinicaltrials |
| NCT07131202 | A Study of FL115 in Combination With a PD-1 Antibody in Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 130 | Suzhou Forlong Biotechnology Co., LtdINDUSTRY | 1 | Jan 8, 2026 | clinicaltrials |
| NCT07321574 | A Study Evaluating the Efficacy and Safety of ABP1011T Tablets in Patients With Advanced Solid Tumors(ABP1011T-03) | recruiting | Phase 2 | 110 | Shanghai AB PharmaTech Ltd.INDUSTRY | 1 | Jan 7, 2026 | clinicaltrials |
| NCT05584800 | Study of ZGGS18 in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 222 | Suzhou Zelgen Biopharmaceuticals Co.,LtdINDUSTRY | 1 | Jan 5, 2026 | clinicaltrials |
| NCT06938880 | Study of ZGGS18 in Combination With ZG005 in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 60 | Suzhou Zelgen Biopharmaceuticals Co.,LtdINDUSTRY | 1 | Jan 5, 2026 | clinicaltrials |
| NCT07124117 | A Study Evaluating OBI-902 in Participants With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 147 | OBI Pharma, IncINDUSTRY | 2 | Jan 5, 2026 | clinicaltrials |
| NCT04353375 | HMPL-453 Tartrate in Advanced Intrahepatic Cholangiocarcinoma | recruiting | Phase 2 / Phase 3 | 235 | HutchmedINDUSTRY | 1 | Dec 31, 2025 | clinicaltrials |
| NCT07265622 | First-in-human Study of 7MW4911 in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 200 | Mabwell (Shanghai) Bioscience Co., Ltd.INDUSTRY | 1 | Dec 29, 2025 | clinicaltrials |
| NCT07197827 | A Study of YL242 in Subjects With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 424 | MediLink Therapeutics (Suzhou) Co., Ltd.INDUSTRY | 3 | Dec 24, 2025 | clinicaltrials |
| NCT06459973 | A Clinical Study of YL205 in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 252 | MediLink Therapeutics (Suzhou) Co., Ltd.INDUSTRY | 2 | Dec 23, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Mar 13, 2026source: clinicaltrials